Spero Therapeutics, Inc. Research and Development Expense
Spero Therapeutics, Inc. (SPRO) reported Research and Development Expense of $3.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Spero Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $3.43M, a 67.82% decline year-over-year.
- Spero Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $2.91M, a 78.62% decline year-over-year.
- Spero Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $5.59M, a 80.61% decline year-over-year.
- Spero Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $8.60M, a 68.00% decline year-over-year.
- Spero Therapeutics, Inc. research and development expense for fiscal 2025 was $38.47M, a 60.24% decline from fiscal 2024.
- Spero Therapeutics, Inc. research and development expense for fiscal 2024 was $96.76M, a 88.10% increase from fiscal 2023.
- Spero Therapeutics, Inc. research and development expense for fiscal 2023 was $51.44M, a 8.08% increase from fiscal 2022.
- Spero Therapeutics, Inc. research and development expense for fiscal 2022 was $47.59M, a 26.24% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.43M 10-Q · filed 2026-08-12 | $6.34M 10-Q · filed 2026-08-12 | $11.94M derived: sum of 3 quarters · filed 2026-08-12 | $20.53M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.91M 10-Q · filed 2026-05-13 | $8.50M derived: sum of 2 quarters · filed 2026-05-13 | $17.10M derived: sum of 3 quarters · filed 2026-05-13 | $27.77M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $5.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $14.19M derived: sum of 2 quarters · filed 2026-03-26 | $24.86M derived: sum of 3 quarters · filed 2026-08-12 | $38.47M 10-K · filed 2026-03-26 |
| 2025-09-30 | $8.60M 10-Q · filed 2025-11-13 | $19.27M derived: sum of 2 quarters · filed 2026-08-12 | $32.88M 10-Q · filed 2025-11-13 | $61.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $10.67M 10-Q · filed 2026-08-12 | $24.28M 10-Q · filed 2026-08-12 | $53.11M derived: sum of 3 quarters · filed 2026-08-12 | $79.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $13.61M 10-Q · filed 2026-05-13 | $42.44M derived: sum of 2 quarters · filed 2026-05-13 | $69.31M derived: sum of 3 quarters · filed 2026-05-13 | $93.03M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $28.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $55.70M derived: sum of 2 quarters · filed 2026-03-26 | $79.42M derived: sum of 3 quarters · filed 2026-03-26 | $96.76M 10-K · filed 2026-03-26 |
| 2024-09-30 | $26.86M 10-Q · filed 2025-11-13 | $50.59M derived: sum of 2 quarters · filed 2025-11-13 | $67.92M 10-Q · filed 2025-11-13 | $84.48M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $23.73M 10-Q · filed 2025-08-12 | $41.06M 10-Q · filed 2025-08-12 | $57.61M derived: sum of 3 quarters · filed 2025-08-12 | $74.01M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $17.33M 10-Q · filed 2025-05-13 | $33.89M derived: sum of 2 quarters · filed 2025-05-13 | $50.28M derived: sum of 3 quarters · filed 2025-05-13 | $59.79M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $16.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $32.95M derived: sum of 2 quarters · filed 2025-03-27 | $42.46M derived: sum of 3 quarters · filed 2025-03-27 | $51.44M 10-K · filed 2025-03-27 |
| 2023-09-30 | $16.39M 10-Q · filed 2024-11-14 | $25.90M derived: sum of 2 quarters · filed 2024-11-14 | $34.88M 10-Q · filed 2024-11-14 | $49.97M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $9.51M 10-Q · filed 2024-08-05 | $18.49M 10-Q · filed 2024-08-05 | $33.58M derived: sum of 3 quarters · filed 2024-08-05 | $40.94M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $8.98M 10-Q · filed 2024-05-15 | $24.07M derived: sum of 2 quarters · filed 2024-05-15 | $31.43M derived: sum of 3 quarters · filed 2024-05-15 | $39.60M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $15.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $22.45M derived: sum of 2 quarters · filed 2024-03-13 | $30.62M derived: sum of 3 quarters · filed 2024-03-13 | $47.59M 10-K · filed 2024-03-13 |
| 2022-09-30 | $7.36M 10-Q · filed 2023-11-13 | $15.53M derived: sum of 2 quarters · filed 2023-11-13 | $32.50M 10-Q · filed 2023-11-13 | $49.73M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $8.17M 10-Q · filed 2023-08-10 | $25.14M 10-Q · filed 2023-08-10 | $42.37M derived: sum of 3 quarters · filed 2023-08-10 | $56.80M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $16.97M 10-Q · filed 2023-05-11 | $34.20M derived: sum of 2 quarters · filed 2023-05-11 | $48.63M derived: sum of 3 quarters · filed 2023-05-11 | $63.09M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $17.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $31.66M derived: sum of 2 quarters · filed 2023-03-30 | $46.12M derived: sum of 3 quarters · filed 2023-03-30 | $64.53M 10-K · filed 2023-03-30 |
| 2021-09-30 | $14.44M 10-Q · filed 2022-11-14 | $28.90M derived: sum of 2 quarters · filed 2022-11-14 | $47.30M 10-Q · filed 2022-11-14 | $60.51M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $14.46M 10-Q · filed 2022-08-10 | $32.87M 10-Q · filed 2022-08-10 | $46.07M derived: sum of 3 quarters · filed 2022-08-10 | $63.78M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $18.40M 10-Q · filed 2022-05-16 | $31.61M derived: sum of 2 quarters · filed 2022-05-16 | $49.31M derived: sum of 3 quarters · filed 2022-05-16 | $64.97M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $30.91M derived: sum of 2 quarters · filed 2022-03-31 | $46.57M derived: sum of 3 quarters · filed 2022-03-31 | $67.00M 10-K · filed 2022-03-31 |
| 2020-09-30 | $17.71M 10-Q · filed 2021-11-10 | $33.36M derived: sum of 2 quarters · filed 2021-11-10 | $53.80M 10-Q · filed 2021-11-10 | $79.53M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $15.66M 10-Q · filed 2021-08-05 | $36.09M 10-Q · filed 2021-08-05 | $61.82M derived: sum of 3 quarters · filed 2021-08-05 | $80.31M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $20.44M 10-Q · filed 2021-05-06 | $46.16M derived: sum of 2 quarters · filed 2021-05-06 | $64.66M derived: sum of 3 quarters · filed 2021-05-06 | $76.69M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $25.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $44.22M derived: sum of 2 quarters · filed 2021-03-11 | $56.25M derived: sum of 3 quarters · filed 2021-03-11 | $65.78M 10-K · filed 2021-03-11 |
| 2019-09-30 | $18.50M 10-Q · filed 2020-11-05 | $30.52M derived: sum of 2 quarters · filed 2020-11-05 | $40.05M 10-Q · filed 2020-11-05 | $49.17M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $12.03M 10-Q · filed 2020-08-06 | $21.55M 10-Q · filed 2020-08-06 | $30.68M derived: sum of 3 quarters · filed 2020-08-06 | $39.14M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $9.53M 10-Q · filed 2020-05-08 | $18.65M derived: sum of 2 quarters · filed 2020-05-08 | $27.11M derived: sum of 3 quarters · filed 2020-05-08 | $34.49M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $17.59M derived: sum of 2 quarters · filed 2020-03-16 | $24.96M derived: sum of 3 quarters · filed 2020-03-16 | $33.88M 10-K · filed 2020-03-16 |
| 2018-09-30 | $8.46M 10-Q · filed 2019-11-04 | $15.83M derived: sum of 2 quarters · filed 2019-11-04 | $24.76M 10-Q · filed 2019-11-04 | $37.26M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $7.37M 10-Q · filed 2019-08-08 | $16.30M 10-Q · filed 2019-08-08 | $28.80M derived: sum of 3 quarters · filed 2019-08-08 | $35.71M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $8.93M 10-Q · filed 2019-05-09 | $21.43M derived: sum of 2 quarters · filed 2019-05-09 | $28.34M derived: sum of 3 quarters · filed 2019-05-09 | $35.80M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $19.41M derived: sum of 2 quarters · filed 2019-03-14 | $26.87M derived: sum of 3 quarters · filed 2019-03-14 | $32.87M 10-K · filed 2019-03-14 |
| 2017-09-30 | $6.91M 10-Q · filed 2018-11-08 | $14.37M derived: sum of 2 quarters · filed 2018-11-08 | $20.37M 10-Q · filed 2018-11-08 | $27.29M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $7.46M 10-Q · filed 2018-08-09 | $13.46M 10-Q · filed 2018-08-09 | $20.38M derived: sum of 3 quarters · filed 2019-03-14 | $26.39M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-03-31 | $6.00M 10-Q · filed 2018-05-10 | $12.93M derived: sum of 2 quarters · filed 2019-03-14 | $18.93M derived: sum of 3 quarters · filed 2019-03-14 | |
| 2016-12-31 | $6.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $12.93M derived: sum of 2 quarters · filed 2019-03-14 | $26.33M 10-K · filed 2019-03-14 | |
| 2016-09-30 | $6.00M 10-Q · filed 2017-12-14 | $19.41M 10-Q · filed 2017-12-14 | ||
| 2015-12-31 | $11.13M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |